Listed

Agape ATP Corp: Form 10-Q for the period ended Mar 31, 2019

Filed with the SEC on May 13, 2019 and accepted by EDGAR at May 13, 2019, 06:21 ET.

Share

Management's discussion and analysis

As filed, 7,951 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The information contained in this quarter report on Form 10-Q is intended to update the information contained in our Form 10-K, dated September 27, 2018, for the year ended June 30, 2018 and presumes that readers have access to, and will have read, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other information contained in such Form 10-K. The following discussion and analysis also should be read together with our consolidated financial statements and the notes to the consolidated financial statements included elsewhere in this Form 10-Q.

The following discussion contains certain statements that may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements appear in a number of places in this Report, including, without limitation, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements are not guarantees of future performance and involve risks, uncertainties and requirements that are difficult to predict or are beyond our control. Forward-looking statements speak only as of the date of this quarterly report. You should not put undue reliance on any forward-looking statements. We strongly encourage investors to carefully read the factors described in our Form S-1 Amendment No.2, dated October 26, 2017, in the section entitled “Risk Factors” for a description of certain risks that could, among other things, cause actual results to differ from these forward-looking statements. We assume no responsibility to update the forward-looking statements contained in this transition report on Form 10-Q. The following should also be read in conjunction with the unaudited Condensed Consolidated Financial Statements and notes thereto that appear elsewhere in this report.

Company Overview

Agape ATP Corporation., a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016. Agape ATP Corporation is a company that operates through its wholly owned subsidiary, Agape ATP Corporation, a company incorporated in Labuan, Malaysia. Our wholly owned subsidiary, Agape ATP Corporation owns 100% of Agape ATP International Holding Limited, the operating Hong Kong company.

Agape ATP Corporation is a company which plans to develop and provide health solution advisory services to our future clients. We will, at least initially, primarily focus our efforts on attracting customers in Malaysia. Our advisory services will center around the “ATP Zeta Health Program”, which is a health program designed to assist in the elimination of various diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition, and advice from skilled dieticians.

At its core, the ATP Zeta Super Health Program is focused upon biological energy, Adenosine Triphosphate (ATP), at the cellular level. The stimulation of ATP production at the cellular level can increase the metabolism and service to promote and maintain normal and healthy functioning of the body’s systems. Our program emphasizes nutrient absorption through the membrane ion channel to provide complete and balanced nutrients to improve cell health. Thus, ATP Zeta Super Health Program provides ionized and high zeta potential (high bioavailability) nutrients to enhance the absorption at the cellular level.

Results of Operation

For the three months ended March 31, 2019 and 2018

Revenues

For three months ended March 31, 2019, the Company has generated revenue of $464,297. The revenue mainly derived from the sale of healthy food products. For three month ended March 31, 2018, the Company has generated no revenue.

Net Profit

For the three months ended March 31, 2019 the Company generated net profit of $71,215 as compared to net loss of $24,676 for the three months ended March 31, 2018. We attribute the net profit in 2019 due to revenue generated while in 2018 there was zero revenue. During the quarter under review, the Company has also managed to keep selling, administrative and general expenses at a level similar to the corresponding period in 2018. For the three months ended March 31, 2019, there was also a write-back of tax provision of $6,965. The tax provision for the Company’s subsidiary in Hong Kong is not required as the tax regime in Hong Kong exempts taxation on business profits derived outside the Special Administrative Region.

For the nine months ended March 31, 2019 and 2018

Revenues

For nine months ended March 31, 2019 and 2018, the Company has generated revenue of $1,149,585 and $487,626 respectively. The revenue mainly derived from the sale of healthy food products.

Our gross profits for the nine months ended March 31, 2019 were $110,052, which is more than $64,398 for nine months ended March 31, 2018. We attribute the increase in revenue and gross profit to increase of market exposure and a wider range of products. We believe that in order to retain and maintain more customers in the future we must increase our marketing efforts and or develop new products.

Net Loss

Our net loss for nine months ended March 31, 2019 were $71,231, while for nine months ended March 31, 2018 were $202,015. We attribute the net loss decreased due to lower selling, administrative and general expenses and the increasing revenue which resulted in higher gross profit.

Liquidity and Capital Resources

As at March 31, 2019, we had working capital surplus of $3,798,733 consisting of cash and cash equivalents of $3,091,401 as compared to working capital surplus of $3,766,446 and cash and cash equivalents of $3,531,255 as of June 30, 2018.

Cash Provided by/Used in Operating Activities

For the nine months ended March 31, 2019, net cash used in operating activities was $444,725. The operating cash flow performance primarily reflects the deposits received from customer of the Company and share of results of investment in investee company.

For the nine months ended March 31, 2018, net cash used in operating activities was $260,933. The operating cash flow performance primarily reflects the increasing account receivables of the Company.

Cash Provided by/Used in Financing Activities

For the nine months ended March 31, 2019, there was no net cash provided by or used in financing activities.

For the nine months ended March 31, 2018, net cash provided by financing activities was $2,925,500, reflecting the proceeds from the issuance of common stock.

Cash Provided by/Used in Investing Activities

For the nine months ended March 31, 2019, net cash used by investing activities was $1,000. The investing cash flow is reflecting the investment in marketable securities.

For the nine months ended March 31, 2018, net cash used by investing activities was $893,592. The investing cash flow is reflecting the investment in investee company.

Credit Facilities

We do not have any credit facilities or other access to bank credit.

Off-balance Sheet Arrangements

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders as of March 31, 2019.

Recent Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Market risk

As filed, 147 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

Controls and procedures

As filed, 1,696 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures:

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2019. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2019, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of March 31, 2019, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

Changes in Internal Control over Financial Reporting:

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2019, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 163 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue9 months2018-07-01 to 2019-03-31$1.1mus-gaap:Revenues
Cost of revenue3 months2019-01-01 to 2019-03-31$420.2kus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2018-07-01 to 2019-03-31$1.0mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2019-01-01 to 2019-03-31$44.1kus-gaap:GrossProfit
Gross profit9 months2018-07-01 to 2019-03-31$110.1kus-gaap:GrossProfit
Selling, general and administrative3 months2019-01-01 to 2019-03-31$28.2kus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2018-07-01 to 2019-03-31$138.9kus-gaap:SellingGeneralAndAdministrativeExpense
Income tax3 months2019-01-01 to 2019-03-31−$7.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-01-01 to 2019-03-31$71.2kus-gaap:NetIncomeLoss
Net income9 months2018-07-01 to 2019-03-31−$71.2kus-gaap:NetIncomeLoss
Diluted EPS3 months2019-01-01 to 2019-03-31$0.02us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2018-07-01 to 2019-03-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2018-07-01 to 2019-03-31−$435.7kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2019-03-31$3.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-03-31$3.9mus-gaap:AssetsCurrent
Total assetsAt period end2019-03-31$5.1mus-gaap:Assets
Current liabilitiesAt period end2019-03-31$91.5kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-03-31$91.5kus-gaap:Liabilities
Shareholders' equityAt period end2019-03-31$5.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-19-006848. Last ingested by Listed: Nov 6, 2026, 16:53 ET. Listed shows no prices and gives no investment advice.